Organic Active Ingredients TRIZ Cases

Biodegradable particles release chemotherapeutic agents locally to target cancer cells, reducing wound healing interference.

Formula I compounds inhibit ASK1 and ASK2 signaling to treat autoimmune, inflammatory, cardiovascular, and neurodegenerative diseases.

Conjugating cisplatin with amino acids targets LAT1 transporters to concentrate drug at tumor sites while reducing systemic toxicity.

Novel phenylacetamide compounds inhibit Rho kinases, addressing unmet needs for treating resistant cardiovascular diseases.

Solvent extraction of unfermented beans followed by milling reduces bitterness while maintaining high polyphenol concentration.

A water and ethanol co-solvent system precipitates gefitinib Form 1, reducing solvent consumption while maintaining batch uniformity.

Thiol linkers join hyaluronic acid to flavonoids, forming stable conjugates that autoxidize into hydrogels with improved bioavailability.

Combination therapies neutralize TNFR1, TRAIL-R, and CD95 to block cell death pathways, addressing limitations of single-agent TNF inhibitors.

Segmented fused pyrimidine structures achieve selective RET inhibition, eliminating off-target side effects from non-specific kinase activity.

Novel CGRP receptor antagonist compounds with specific ring systems and linker groups treat migraine disorders by improving treatment effectiveness.

Granules with controlled surface pores accommodate micronized drugs to enhance loading capacity and maintain formulation flow properties.

Introducing substituted guanidine groups into imidazoquinoline cores resolves the trade-off between structural complexity and cytokine induction capability.

Ion implantation embeds boron or gadolinium into nanodiamonds, increasing tumor loading capacity while protecting normal cells from damage.

Benzoxazolone urea scaffolds modulate ceramide levels by optimizing R1-R6 substituents to resolve potency and stability trade-offs.

Novel TRPC6 inhibitor compounds modulate ion flux to resolve therapeutic effectiveness gaps in treating hypertension and fibrotic disorders.

Recrystallizing free prasugrel removes OXTP impurities before salt formation, achieving 95% purity.

Combining HE4 inhibition with immune checkpoint blockade sensitizes cells to chemotherapy, addressing limited efficacy in single-agent cancer therapies.

Tetracyclic pyridone compounds reduce viral load and subviral particle abundance while preventing drug-resistant mutant persistence.

SNS-595 dosing regimens resolve efficacy and toxicity trade-offs through precise parameter adjustments.

A sterile viscous gel adheres to sinus mucosa, preventing drug waste and reducing systemic side effects.

Cyclic hydrazone compounds suppress IL-12 and TH1 cell proliferation, addressing persistent pro-inflammatory cytokine production in autoimmune treatments.

An acetal ester linker in the aptamer-triptolide conjugate overcomes low acid sensitivity of prior art by cleaving in the acidic lysosomal environment.

Segmenting broad inhibition into selective targeting resolves the specificity trade-off while maintaining therapeutic reliability.

Novel biphenyl triazol structures achieve nanomolar IC50 values for STIM1/Orai1 modulation without cytotoxicity.

Modified carnosine esters scavenge reactive species while resisting enzymatic degradation, restoring cellular function in pancreatic beta-cells.

Segmented gemcitabine instillation overcomes short dwell time limitations, reducing systemic toxicity while sustaining therapeutic tissue levels.

A composition using fucosterol and Sargassum fulvellum extracts to enhance muscle protein synthesis via p-mTOR activation.

pH-controlled aqueous GLYX-13 formulations prevent degradation in solution, enabling efficient blood-brain barrier transport for treating CNS disorders.

N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)phenyl]sulfonamides inhibit serum and glucocorticoid regulated kinase 1.

Formula I compounds reduce viral load and extend protection windows against mutating strains by targeting conserved regions.

Steviol glycosides combined with carbohydrates and proteins accelerate glycogen re-synthesis, resolving prolonged recovery times after exhaustive exercise.

Ethyl cellulose formulations incorporate 2-mercaptobenzimidazole as an intermediary antioxidant to suppress impurity generation during long-term storage.

Combining phenoxypyrimidinone compounds with insulin potentiates glucose control, reducing injection frequency.

Acid addition salts convert unstable hydroxynorketamine oils into crystalline solids with high aqueous solubility.

Formula I compounds inhibit AhR activity, resolving the trade-off between detoxification and pro-cancerogen metabolism in cancer treatment.

Macrocyclic compounds featuring a fluorinated pyrimidine core and substituted sulfonyl-methylene group enhance potency as CDK9 inhibitors.

CXCL12 biomarker analysis selects tipifarnib candidates for angioimmunoblastic T-cell lymphoma, improving response rates.

An ethanol and surfactant mixture solubilizes a low-solubility active compound, maintaining chemical stability for at least 24 hours after dilution.

Segmented substituted pyrimidine derivatives resist specific kinase families, resolving the trade-off between broad treatment coverage and off-target effects.

Patsnap Eureka TRIZ case shows recombinant EGFL7 antibodies targeting acute myeloid leukemia blasts to overcome poor prognostic accuracy.

Novel 23-yne vitamin D3 derivative enhances bone mineral density without excessive serum calcium elevation.

Thermosensitive bio-adhesive hydrogel encapsulates renal stone fragments and protects urothelium during lithotripsy procedures.

Direct filling of nascent lipid nanoparticles into primary packaging containers followed by freeze drying eliminates deep-freeze storage requirements.

A pomalidomide pharmaceutical composition uses specific binders and fillers to enhance drug dissolution rates within oral capsules.

Developing stable crystalline hydrates of FTY720 hydrochloride resolves polymorphism issues, ensuring consistent therapeutic efficacy.

Alternating FGFR and PLK1 inhibitor cycles resolves acquired resistance while maintaining manageable treatment complexity to enhance tumor regression.

Bicyclic amine compounds act as positive allosteric modulators for the GABAA alpha5 receptor subtype.

A tumor tissue-penetrating peptide binds neuropilin 1 to enhance drug delivery into cancer tissues.

An iron-dextran complex combined with polyvinyl pyrrolidone resolves the contradiction between high hematinic efficacy and iron toxicity in piglets.

Small molecule compounds modulate TNF superfamily costimulatory interactions through targeted binding affinity.

Attenuated Salmonella typhimurium delivers chemotherapy agents to tumors, reducing systemic toxicity while maintaining efficacy.

Novel DGAT2 inhibitor compounds reduce triglyceride levels and LDL-c production, addressing statin intolerance in cardiovascular disease treatment.

Specified PARP7 inhibitor dosages treat cancer while minimizing adverse effects and immune evasion.

A biocompatible sheet uses independent holes to hold bioactive substances separately.

RNA interference agents target the LPA gene to lower lipoprotein(a) levels, addressing limited treatment options for cardiovascular disease.

Ciclesonide prodrug converts to active metabolite in lungs, preventing growth suppression.

Stereoselective process converts neopterin to tetrahydrobiopterin via selective protection and reduction steps.

Dietary fucose administration alters tumor glycosylation patterns to enhance immune cell infiltration and suppress cancer progression.

Quantifying specific gut bacterial taxa resolves diagnostic ambiguity between ulcerative colitis and Crohn's disease.

Phenylsulfonyl triazole methanones reduce local estrogen and testosterone levels in endometriotic tissues.

Rhamnosidase cleaves rhamnose from sparingly soluble flavonoids with cyclodextrin to form water-soluble inclusion compounds, resolving low bioavailability.

Local glucopyranosyl lipid adjuvant administration prevents perioperative metastasis while avoiding systemic adverse reactions.

Water-soluble binders create a solid dosage matrix that controls the release of highly lipophilic substances, resolving low water solubility issues.

A pharmaceutical composition combines a PPARδ agonist with croscarmellose sodium to enhance dissolution stability.

2'-Alkynyl substituted nucleoside derivatives inhibit HCV NS5B polymerase activity to address inadequate chronic infection clearance rates.

A controlled-release lipid formulation delivers buprenorphine to infants with neonatal abstinence syndrome.

Tipiracil inhibits thymidine phosphorylase to reduce platelet activation, lipid accumulation, and atherosclerotic plaques without systemic side effects.

Phosphoric acid hydrolyzes clinoptilolite into water-soluble fragments, enabling GI absorption and systemic heavy metal binding.

Vectors ectopically express receptors on non-native cells, enabling conjugated compounds to bind and reduce target genes effectively.

Titration of intravenous ranolazine achieves rapid stabilization while minimizing adverse effects through controlled parameter adjustment.

Self-complementary polynucleotide structures enable multivalent RNA interference, reducing off-target effects and toxicity while sustaining gene inhibition.

Second-generation thiazolidinediones target the mitochondrial pyruvate carrier to treat NASH while avoiding PPARγ side effects.

MDA-targeted CARs bridge T cells and melanoma cells to overcome immune-escape mechanisms and enhance treatment reliability.

A cholesterol and cellulose composite coating enhances drug delivery speed on medical balloons.

Culturing stem cells with ligustilide improves survival and homing while reducing inflammatory reactions in stroke therapy.

Segmented analysis of ARID1A and PPP2R1A genes enables precise mutation detection using specialized molecular techniques.

Cyclone deagglomerator breaks powder agglomerates to ensure small particle sizes, reducing salmeterol exposure and cardiac side-effects.

A pre-filled syringe injection device integrates the needle and shield with the plunger rod to deliver vitamin K1.

Piperazine carbamate compounds inhibit monoacylglycerol lipase and serine hydrolase activity through specific molecular binding mechanisms.

Salt formation and polymorph development yield non-hygroscopic, thermally stable compounds for dyslipidemia treatment.

Segmented measurement of ENPP2 and LPA biomarkers improves prediction accuracy while managing diagnostic complexity for infected subjects.

Segmented nanoparticles protect nucleic acids from degradation while reducing systemic toxicity through targeted delivery.

Lactose-free micronized cytisine capsules prevent Maillard reactions and thermal degradation during low-temperature tableting.

A miR-485 inhibitor decreases NLRP3 protein and gene expression levels.

Obacunone medicament treats lung injury and pulmonary fibrosis by regulating inflammation cytokines while maintaining low toxicity.

Hydroxyprogesterone caproate treats interstitial pneumonia by reducing collagen deposition and resolving glucocorticoid resistance side effects.

Crystalline menin/MLL inhibitors resolve ineffective leukemia therapies by blocking oncogenic protein interactions.

Heteroaryl sultam compounds target RORγ to improve selectivity over other receptors, resolving efficacy trade-offs in autoimmune disease treatment.

Benzimidazole derivatives with heteroaryl substituents activate glucokinase to improve glucose homeostasis in diabetes treatment.

Structural modifications reduce hepatic metabolism and dissociative side effects while maintaining oral bioavailability.

Pyrimido[5,4-d]pyrimidine compounds inhibit HER2 mutations while crossing the blood-brain barrier to treat brain metastases.

A modified release epalrestat composition utilizes pH-dependent solubility to achieve sustained plasma concentrations.